Karla C.M. de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karla C.M. de Oliveira has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Alexandre S. Bruno
Department of Pharmacology, Institute of Biological Science, Federal University of Minas Gerais, MG, Brazil
1 shared publication- Anizia K. de Oliveira
Department of Pharmacology, Institute of Biological Science, Federal University of Minas Gerais, MG, Brazil
1 shared publication - Casey G. Turner
Auburn University
1 shared publication Iris Z. Jaffe
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
1 shared publication- Jennifer J. DuPont
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA
1 shared publication - Patricia Lopes
Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
1 shared publication
Latest Publications
- 25 April 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103591
Mineralocorticoid and estrogen receptors as sex-dependent modulators of vascular health in aging and obesity
- 25 April 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103591
Mineralocorticoid and estrogen receptors as sex-dependent modulators of vascular health in aging and obesity
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 17 (1) , 35-46
Vascular Inflammation in Hypertension: Targeting Lipid Mediators Unbalance and Nitrosative Stress
: Arterial hypertension is a worldwide public health threat. High Blood Pressure (BP) is commonly associated with endothelial dysfunction, nitric oxide synthases (NOS) unbalance and high peripheral vascular resistance. In addition to those, inflammation has also been designated as one of the major components of BP increase and organ damage in hypertension. This minireview discusses vascular inflammatory triggers of high BP and aims to fill the existing gaps of antiinflammatory therapy of hypertension. Among the reasons discussed, enhanced prostaglandins rather than resolvins lipid mediators, immune cell infiltration and oxidative/nitrosative stress are pivotal players of BP increase within the inflammatory hypothesis. To address these inflammatory targets, this review also proposes new concepts in hypertension treatment with non-steroidal antiinflammatory drugs (NSAIDs), nitric oxide-releasing NSAIDs (NO-NSAIDs) and specialized proresolving mediators (SPM). In this context, the failure of NSAIDs in hypertension treatment seems to be associated with the reduction of endogenous NO bioavailability, which is not necessarily an effect of all drug members of this pharmacological class. For this reason, NO-releasing NSAIDs seem to be safer and more specific therapy to treat vascular inflammation in hypertension than regular NSAIDs.
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 17 (1) , 35-46
Vascular Inflammation in Hypertension: Targeting Lipid Mediators Unbalance and Nitrosative Stress
: Arterial hypertension is a worldwide public health threat. High Blood Pressure (BP) is commonly associated with endothelial dysfunction, nitric oxide synthases (NOS) unbalance and high peripheral vascular resistance. In addition to those, inflammation has also been designated as one of the major components of BP increase and organ damage in hypertension. This minireview discusses vascular inflammatory triggers of high BP and aims to fill the existing gaps of antiinflammatory therapy of hypertension. Among the reasons discussed, enhanced prostaglandins rather than resolvins lipid mediators, immune cell infiltration and oxidative/nitrosative stress are pivotal players of BP increase within the inflammatory hypothesis. To address these inflammatory targets, this review also proposes new concepts in hypertension treatment with non-steroidal antiinflammatory drugs (NSAIDs), nitric oxide-releasing NSAIDs (NO-NSAIDs) and specialized proresolving mediators (SPM). In this context, the failure of NSAIDs in hypertension treatment seems to be associated with the reduction of endogenous NO bioavailability, which is not necessarily an effect of all drug members of this pharmacological class. For this reason, NO-releasing NSAIDs seem to be safer and more specific therapy to treat vascular inflammation in hypertension than regular NSAIDs.